Clinical trials: Controlled Asthma
- Condition Controlled Asthma
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Asthma
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists
This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled…
- Trial name
- NCT05110976
- Testing
- AZD8630
- Where
- 29 sites in United States, Germany and 1 more
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects
A combination of the corticosteroid GW685698X and the long-acting ß2-agonist GW642444M is being developed for once daily administration for the maintenance treatment of asthma and COPD.
- Trial name
- NCT00625196
- Testing
- Fluticasone foroate/ vilanterol, Fluticasone foroate, Vilanterol
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers
This is a randomized, double-blind, placebo-controlled Phase 1 study of HA115 capsules administered orally to healthy adult volunteers.
- Trial name
- NCT03567694
- Testing
- HA115
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Healthy Adult Participants, Asthma Exacerbation
RIG 101 Trial in Healthy Adults and Adults With Asthma
Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy
- Conditions
- Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
- Trial name
- NCT07488897
- Testing
- RIG-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- RIGImmune Inc.
Healthy, Asthma
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent…
- Trial name
- NCT02243189
- Testing
- JNJ-43260295, Nasal Allergen Challenge
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Health Adults, Asthma
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.
- Trial name
- NCT07900568
- Testing
- HXN-1013
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Mild to Moderate Asthma
Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Phase 1 of this study will consist of 2 parts Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous…
- Trial name
- NCT07245368
- Testing
- PRA-216
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Prana Therapies Inc
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140320
- Testing
- RV1729 single dose, RV1729 14 day repeat dose, RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects.
- Trial name
- NCT04445038
- Testing
- 610
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Safety and Blood Level Study of Unit Dose Budesonide
The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.
- Trial name
- UDB P101 (NCT00627679)
- Testing
- Budesonide Inhalation Suspension, MAP0010 low dose, MAP0010 intermediate dose
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Allergan
Asthma
A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma
This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.
- Trial name
- AIR645-CS1 (NCT00658749)
- Testing
- AIR645, Physiologic saline solution
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Altair Therapeutics, Inc.
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Asthma
Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma
The purpose of this study is to evaluate the safety and tolerability of the dry powder formulation of ASM-024 following single and multiple administration by inhalation of ascending doses in healthy subjects and subjects with…
- Trial name
- NCT01793298
- Testing
- ASM-024
- Where
- 2 sites in Canada
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Asmacure Ltée
Asthma
A Study of GW685698X in Healthy Japanese Male Subjects
This is a randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy…
- Trial name
- NCT00972673
- Testing
- GW685698X
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Atopic Dermatitis
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of single ascending dose of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose administered IV in participants with asthma and…
- Conditions
- Asthma, Atopic Dermatitis, Healthy
- Trial name
- NCT02345928
- Testing
- Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, Part 2 (Atopic Dermatitis): CNTO 7160
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Asthma
Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects
A combination of the corticosteroid GW685698X and the long-acting ß2-agonist GW642444M is being developed for once daily administration for the maintenance treatment of asthma and COPD.
- Trial name
- NCT00538057
- Testing
- GW685698X & GW642444M
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers
To evaluate the pharmacokinetic (PK) characteristics and pharmacological effect of GR2002 injection in Chinese healthy volunteers
- Trial name
- NCT05954611
- Testing
- GR2002 injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Asthma
A Trial of HBM9378 in Healthy Chinese Subjects
The objective is to evaluate the safety, tolerability and pharmacokinetic profile of a single subcutaneous injection of HBM9378 (SKB378) at different doses in healthy Chinese subjects.
- Trial name
- NCT05790694
- Testing
- HBM9378 (SKB378) Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Asthma
Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8
The study focusses on the evaluation of safety and tolerability of the XC8. The design of the study involves sequential dosing of cohorts (group of volunteers), taking increasing doses of the product after receiving conclusion…
- Trial name
- NCT02882217
- Testing
- XC8 (histamine glutarimide)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- EURRUS Biotech GmbH